Stem cell therapy is not a proven treatment for autism. It is not an NHS treatment, not supported by NICE for the core features of autism, and still investigational. No regulatory authority has approved stem cell therapy specifically for autism.
There is some early-stage research — mostly small trials with significant limitations — suggesting that certain types of stem cells may have modest effects on some autism-related symptoms. But the evidence is nowhere near strong enough to justify the claims being made by commercial clinics, many of which charge families tens of thousands of pounds for unregulated procedures abroad.
This guide explains what the research actually shows, why families are drawn to stem cell therapy, and how to tell the difference between legitimate science and exploitation.
🚫 What stem cell therapy is NOT:
🔬 What the research does show:
It is not hard to understand why. Most parents of autistic children will, at some point, search for treatments beyond what the NHS offers. When standard support feels insufficient — when waiting lists are years long, when therapies are underfunded, when progress feels slow — the appeal of something that sounds transformative is powerful.
Stem cell therapy is marketed with language designed to reach exactly those parents. Words like "regenerative," "revolutionary," "neurological repair" and "90% improvement" appear across clinic websites and social media. Some clinics reference real studies. Some show parent testimonials. Some offer packages costing £15,000–£40,000 per round, often requiring multiple rounds.
NPR reported in March 2026 that one US parent had spent $40,000 per year on stem cell treatments in Germany for her autistic son — repeated over three years — alongside other interventions totalling over $100,000.
None of this means stem cell therapy works. It means the marketing is effective and the desperation is real.
Stem cells are cells that can develop into different types of specialised cells in the body. They are found in embryos, in umbilical cord blood and tissue, in bone marrow, and in some adult tissues.
In mainstream medicine, stem cell transplants are established treatments for certain blood cancers, immune disorders and bone marrow failure. These are regulated, evidence-based uses with decades of clinical data.
The types of stem cells being explored for autism are mainly:
The theory behind using them for autism centres on three proposed mechanisms: reducing neuroinflammation, modulating the immune system, and supporting neural repair through the release of growth factors. Whether any of these mechanisms actually operate in a clinically meaningful way in autistic individuals has not been established.
A 2022 meta-analysis published in Frontiers in Pediatrics (5 studies, 325 children) found a statistically significant reduction in CARS scores (Childhood Autism Rating Scale) in stem cell groups compared to controls. However, the authors themselves concluded there was "insufficient evidence regarding the efficacy and safety" and noted significant limitations including small sample sizes, lack of standardised protocols, and limited follow-up.
A separate 2021 meta-analysis (11 trials, 461 participants) reported a mean CARS reduction of -9.08 points — but with high heterogeneity across studies, meaning the results varied substantially from one trial to another.
The most rigorous research has come from Duke University (Dr Joanne Kurtzberg and Dr Geraldine Dawson). Their Phase II randomised controlled trial of cord blood infusions in autistic children found:
This is the best-quality evidence to date, and even it shows benefit only in a narrow subgroup. Duke is continuing research with mesenchymal stromal cells in toddlers, but results are still pending.
A randomised, open-label trial published in Stem Cell Research & Therapy (2025) tested autologous bone marrow mononuclear cells combined with educational intervention in 30 children. It reported improvements in some behavioural measures, but the trial was open-label (not blinded), small, and combined stem cells with education — making it impossible to isolate the effect of the cells.
Most reported side effects in clinical trials have been mild: fever, headache, nausea, temporary behavioural changes (increased hyperactivity or agitation). Serious adverse events have been rare in published studies.
However, clinical trials use carefully controlled procedures. The unregulated clinics that most families encounter are a different matter. Risks from unregulated stem cell treatments include:
Stem cell treatments abroad typically cost £15,000–£40,000 per round. Many clinics recommend multiple rounds. Families have reported spending over £100,000 with no measurable improvement.
Families invest enormous hope in these treatments. When they do not work — which, given the evidence, is the most likely outcome — the disappointment can be devastating. Some parents describe feeling they have "failed" their child again after an unsuccessful round.
Stem cell therapy for autism is not available on the NHS and is not supported by NICE for the core features of autism.
The MHRA (Medicines and Healthcare products Regulatory Agency) regulates stem cell products in the UK. Treatments using more than minimally manipulated cells require a licence. Many clinics operate in a regulatory grey area or simply operate abroad, outside UK oversight entirely.
In April 2024, the Metropolitan Police investigated reports of an individual planning to offer stem cell procedures on autistic children in London (BBC News, April 2024). The MHRA has warned of "dangerous, experimental procedures" offered outside regulated settings.
The International Society for Stem Cell Research (ISSCR) explicitly warns against the premature marketing of unproven stem cell treatments and advises patients to be sceptical of clinics offering stem cell therapies for conditions where the evidence base has not been established.
NICE does not address stem cell therapy for autism specifically because the evidence has not reached the threshold for consideration.
If you are researching stem cell therapy, these are warning signs:
If a clinic cannot provide you with published, peer-reviewed evidence of their specific protocol's safety and efficacy in autistic children, treat their claims with extreme caution.
The idea behind stem cell therapy for autism is not absurd. There is a biological rationale, and a small number of legitimate research teams — particularly at Duke University — are conducting serious, well-designed studies. The science may eventually lead somewhere meaningful.
But "may eventually lead somewhere" is not a reason to spend your family's savings at an unregulated clinic abroad. The evidence today is insufficient. The risks from unregulated treatments are real. And the gap between what the science shows and what the marketing claims is enormous.
If stem cell therapy for autism becomes a proven treatment, it will come through regulated clinical trials, peer-reviewed publication, and eventually, clinical adoption. It will not come from a clinic in Panama charging £30,000 per injection.
There is no specific law banning stem cell therapy for autism, but any product involving more than minimally manipulated cells requires MHRA authorisation. Most clinics offering stem cells for autism operate abroad, outside UK regulatory oversight. The Met Police and MHRA have both acted on clinics attempting to offer unregulated stem cell procedures to autistic children.
No. While some small clinical trials have reported improvements on rating scales like CARS, no large, well-controlled study has demonstrated clear and consistent benefit. The best-quality trial (Duke University Phase II) found benefit only in a narrow subgroup. Every systematic review to date has concluded that the evidence is insufficient.
Typically £15,000–£40,000 per round, with many clinics recommending multiple rounds. Some families have reported total costs exceeding £100,000. These costs are not covered by the NHS or private health insurance in the UK.
Some cord blood banks market their services to expectant parents with the suggestion that banked cord blood could be used for future autism treatment. While cord blood is used in legitimate research (notably at Duke), there is no current evidence that banking your child's cord blood will provide an autism treatment. The decision to bank cord blood should not be driven by autism-specific marketing claims.
ClinicalTrials.gov lists registered studies worldwide. The Duke Marcus Center for Cellular Cures is the leading research group. In the UK, no stem cell trials for autism are currently listed on major registries, but this may change as the research develops.
Focus on evidence-based support: speech and language therapy, occupational therapy, communication support, educational interventions, and regular paediatric follow-up with a clinician who understands autism. See our guides on DLA for autistic children, EHCP applications, and the first 100 days after diagnosis for practical starting points.
Disclaimer: SENDPath provides information for families navigating SEND in Kent and beyond. We are not clinicians. Nothing on this page constitutes medical advice. Always consult a qualified healthcare professional before making treatment decisions for your child.
A clear, evidence-based guide — including the retracted 2024 trial, the FDA's limited 2026 approval, and what UK guidance says.
Read guide →An honest guide to GFCF diets, probiotics, omega-3, vitamins, food selectivity and ARFID — and what UK guidance actually recommends.
Read guide →The GABA theory, Phase 3 results, and what the failure tells us about autism research.
Read guide →The NEJM trial, why early promise didn't translate, and what the evidence says now.
Read guide →